SEC Form 4 · accession 0000899243-17-018152
Eledon Pharmaceuticals, Inc. · ELDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jon Kuwahara
Officer — See Remarks
Period of report
Jul 10, 2017
Accepted (ET)
Jul 10, 2017 · 5:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001404281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.61 | Jul 10, 2017 | A | 35,000 | A | — | Jul 10, 2027 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1This option represents a right to purchase a total of 35,000 shares of the Issuer's Common Stock one quarter of which will become fully vested and exercisable on 7/10/2018, with the remaining 26,250 shares vesting in equal quarterly installments over the following three years.
Remarks
Senior Vice President of Finance and Administration